img

Global Biopharmaceutical CDMO Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Biopharmaceutical CDMO Market Insights, Forecast to 2034

Market Analysis and InsightsGlobal Biopharmaceutical CDMO Market
Global Biopharmaceutical CDMO market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Biopharmaceutical CDMO industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
Globally, Biopharmaceutical CDMO key companies include Lonza, WuXi AppTec, Catalent, Thermo Fisher, Recipharm, Samsung Biologics, Siegfried, Delpharm and Boehringer Ingelheim, etc. Lonza, WuXi AppTec, Catalent are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Biopharmaceutical CDMO were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033 and the share will be % in 2033. Moreover, China, plays a key role in the whole Biopharmaceutical CDMO market and estimated to attract more attentions from industry insiders and investors.
Biopharmaceutical CDMO can be divided into Development and Manufacturing CDMOs, Clinical Trial Material CDMOs, Fill-Finish CDMOs and Other, etc. Development and Manufacturing CDMOs is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2033.
Biopharmaceutical CDMO is widely used in various fields, such as Pharmaceutical Company, Biotechnology Company and Other,, etc. Pharmaceutical Company provides greatest supports to the Biopharmaceutical CDMO industry development. In 2022, global % revenue of Biopharmaceutical CDMO went into Pharmaceutical Company filed and the proportion will reach to % in 2033.
Report Covers
This report presents an overview of global Biopharmaceutical CDMO market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Biopharmaceutical CDMO market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Lonza
WuXi AppTec
Catalent
Thermo Fisher
Recipharm
Samsung Biologics
Siegfried
Delpharm
Boehringer Ingelheim
Aenova Group
AGC Parma Chemicals
GenScript
ProBioGen
KBI Biopharma
3P Biopharmaceuticals
Rentschler Biopharma
Northway Biotech
Segment by Type
Development and Manufacturing CDMOs
Clinical Trial Material CDMOs
Fill-Finish CDMOs
Other

Segment by Application


Pharmaceutical Company
Biotechnology Company
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Biopharmaceutical CDMO introduction, etc. Biopharmaceutical CDMO Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Biopharmaceutical CDMO
Chapter 13Methodology and Data Sources adopted by MRAResearch

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biopharmaceutical CDMO Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Development and Manufacturing CDMOs
1.2.3 Clinical Trial Material CDMOs
1.2.4 Fill-Finish CDMOs
1.2.5 Other
1.3 Market by Application
1.3.1 Global Biopharmaceutical CDMO Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biopharmaceutical CDMO Market Perspective (2018-2033)
2.2 Global Biopharmaceutical CDMO Growth Trends by Region
2.2.1 Biopharmaceutical CDMO Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Biopharmaceutical CDMO Historic Market Size by Region (2018-2023)
2.2.3 Biopharmaceutical CDMO Forecasted Market Size by Region (2024-2033)
2.3 Biopharmaceutical CDMO Market Dynamics
2.3.1 Biopharmaceutical CDMO Industry Trends
2.3.2 Biopharmaceutical CDMO Market Drivers
2.3.3 Biopharmaceutical CDMO Market Challenges
2.3.4 Biopharmaceutical CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Biopharmaceutical CDMO by Players
3.1.1 Global Biopharmaceutical CDMO Revenue by Players (2018-2023)
3.1.2 Global Biopharmaceutical CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Biopharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Biopharmaceutical CDMO, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Biopharmaceutical CDMO Market Concentration Ratio
3.4.1 Global Biopharmaceutical CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biopharmaceutical CDMO Revenue in 2022
3.5 Global Key Players of Biopharmaceutical CDMO Head office and Area Served
3.6 Global Key Players of Biopharmaceutical CDMO, Product and Application
3.7 Global Key Players of Biopharmaceutical CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Biopharmaceutical CDMO Breakdown Data by Type
4.1 Global Biopharmaceutical CDMO Historic Market Size by Type (2018-2023)
4.2 Global Biopharmaceutical CDMO Forecasted Market Size by Type (2024-2033)
5 Biopharmaceutical CDMO Breakdown Data by Application
5.1 Global Biopharmaceutical CDMO Historic Market Size by Application (2018-2023)
5.2 Global Biopharmaceutical CDMO Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Biopharmaceutical CDMO Market Size (2018-2033)
6.2 North America Biopharmaceutical CDMO Market Size by Type
6.2.1 North America Biopharmaceutical CDMO Market Size by Type (2018-2023)
6.2.2 North America Biopharmaceutical CDMO Market Size by Type (2024-2033)
6.2.3 North America Biopharmaceutical CDMO Market Share by Type (2018-2033)
6.3 North America Biopharmaceutical CDMO Market Size by Application
6.3.1 North America Biopharmaceutical CDMO Market Size by Application (2018-2023)
6.3.2 North America Biopharmaceutical CDMO Market Size by Application (2024-2033)
6.3.3 North America Biopharmaceutical CDMO Market Share by Application (2018-2033)
6.4 North America Biopharmaceutical CDMO Market Size by Country
6.4.1 North America Biopharmaceutical CDMO Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Biopharmaceutical CDMO Market Size by Country (2018-2023)
6.4.3 North America Biopharmaceutical CDMO Market Size by Country (2024-2033)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Biopharmaceutical CDMO Market Size (2018-2033)
7.2 Europe Biopharmaceutical CDMO Market Size by Type
7.2.1 Europe Biopharmaceutical CDMO Market Size by Type (2018-2023)
7.2.2 Europe Biopharmaceutical CDMO Market Size by Type (2024-2033)
7.2.3 Europe Biopharmaceutical CDMO Market Share by Type (2018-2033)
7.3 Europe Biopharmaceutical CDMO Market Size by Application
7.3.1 Europe Biopharmaceutical CDMO Market Size by Application (2018-2023)
7.3.2 Europe Biopharmaceutical CDMO Market Size by Application (2024-2033)
7.3.3 Europe Biopharmaceutical CDMO Market Share by Application (2018-2033)
7.4 Europe Biopharmaceutical CDMO Market Size by Country
7.4.1 Europe Biopharmaceutical CDMO Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Biopharmaceutical CDMO Market Size by Country (2018-2023)
7.4.3 Europe Biopharmaceutical CDMO Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Biopharmaceutical CDMO Market Size (2018-2033)
8.2 China Biopharmaceutical CDMO Market Size by Type
8.2.1 China Biopharmaceutical CDMO Market Size by Type (2018-2023)
8.2.2 China Biopharmaceutical CDMO Market Size by Type (2024-2033)
8.2.3 China Biopharmaceutical CDMO Market Share by Type (2018-2033)
8.3 China Biopharmaceutical CDMO Market Size by Application
8.3.1 China Biopharmaceutical CDMO Market Size by Application (2018-2023)
8.3.2 China Biopharmaceutical CDMO Market Size by Application (2024-2033)
8.3.3 China Biopharmaceutical CDMO Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Biopharmaceutical CDMO Market Size (2018-2033)
9.2 Asia Biopharmaceutical CDMO Market Size by Type
9.2.1 Asia Biopharmaceutical CDMO Market Size by Type (2018-2023)
9.2.2 Asia Biopharmaceutical CDMO Market Size by Type (2024-2033)
9.2.3 Asia Biopharmaceutical CDMO Market Share by Type (2018-2033)
9.3 Asia Biopharmaceutical CDMO Market Size by Application
9.3.1 Asia Biopharmaceutical CDMO Market Size by Application (2018-2023)
9.3.2 Asia Biopharmaceutical CDMO Market Size by Application (2024-2033)
9.3.3 Asia Biopharmaceutical CDMO Market Share by Application (2018-2033)
9.4 Asia Biopharmaceutical CDMO Market Size by Region
9.4.1 Asia Biopharmaceutical CDMO Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Biopharmaceutical CDMO Market Size by Region (2018-2023)
9.4.3 Asia Biopharmaceutical CDMO Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Type
10.2.1 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Application
10.3.1 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Country
10.4.1 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Biopharmaceutical CDMO Introduction
11.1.4 Lonza Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.1.5 Lonza Recent Developments
11.2 WuXi AppTec
11.2.1 WuXi AppTec Company Details
11.2.2 WuXi AppTec Business Overview
11.2.3 WuXi AppTec Biopharmaceutical CDMO Introduction
11.2.4 WuXi AppTec Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.2.5 WuXi AppTec Recent Developments
11.3 Catalent
11.3.1 Catalent Company Details
11.3.2 Catalent Business Overview
11.3.3 Catalent Biopharmaceutical CDMO Introduction
11.3.4 Catalent Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.3.5 Catalent Recent Developments
11.4 Thermo Fisher
11.4.1 Thermo Fisher Company Details
11.4.2 Thermo Fisher Business Overview
11.4.3 Thermo Fisher Biopharmaceutical CDMO Introduction
11.4.4 Thermo Fisher Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.4.5 Thermo Fisher Recent Developments
11.5 Recipharm
11.5.1 Recipharm Company Details
11.5.2 Recipharm Business Overview
11.5.3 Recipharm Biopharmaceutical CDMO Introduction
11.5.4 Recipharm Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.5.5 Recipharm Recent Developments
11.6 Samsung Biologics
11.6.1 Samsung Biologics Company Details
11.6.2 Samsung Biologics Business Overview
11.6.3 Samsung Biologics Biopharmaceutical CDMO Introduction
11.6.4 Samsung Biologics Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.6.5 Samsung Biologics Recent Developments
11.7 Siegfried
11.7.1 Siegfried Company Details
11.7.2 Siegfried Business Overview
11.7.3 Siegfried Biopharmaceutical CDMO Introduction
11.7.4 Siegfried Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.7.5 Siegfried Recent Developments
11.8 Delpharm
11.8.1 Delpharm Company Details
11.8.2 Delpharm Business Overview
11.8.3 Delpharm Biopharmaceutical CDMO Introduction
11.8.4 Delpharm Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.8.5 Delpharm Recent Developments
11.9 Boehringer Ingelheim
11.9.1 Boehringer Ingelheim Company Details
11.9.2 Boehringer Ingelheim Business Overview
11.9.3 Boehringer Ingelheim Biopharmaceutical CDMO Introduction
11.9.4 Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.9.5 Boehringer Ingelheim Recent Developments
11.10 Aenova Group
11.10.1 Aenova Group Company Details
11.10.2 Aenova Group Business Overview
11.10.3 Aenova Group Biopharmaceutical CDMO Introduction
11.10.4 Aenova Group Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.10.5 Aenova Group Recent Developments
11.11 AGC Parma Chemicals
11.11.1 AGC Parma Chemicals Company Details
11.11.2 AGC Parma Chemicals Business Overview
11.11.3 AGC Parma Chemicals Biopharmaceutical CDMO Introduction
11.11.4 AGC Parma Chemicals Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.11.5 AGC Parma Chemicals Recent Developments
11.12 GenScript
11.12.1 GenScript Company Details
11.12.2 GenScript Business Overview
11.12.3 GenScript Biopharmaceutical CDMO Introduction
11.12.4 GenScript Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.12.5 GenScript Recent Developments
11.13 ProBioGen
11.13.1 ProBioGen Company Details
11.13.2 ProBioGen Business Overview
11.13.3 ProBioGen Biopharmaceutical CDMO Introduction
11.13.4 ProBioGen Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.13.5 ProBioGen Recent Developments
11.14 KBI Biopharma
11.14.1 KBI Biopharma Company Details
11.14.2 KBI Biopharma Business Overview
11.14.3 KBI Biopharma Biopharmaceutical CDMO Introduction
11.14.4 KBI Biopharma Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.14.5 KBI Biopharma Recent Developments
11.15 3P Biopharmaceuticals
11.15.1 3P Biopharmaceuticals Company Details
11.15.2 3P Biopharmaceuticals Business Overview
11.15.3 3P Biopharmaceuticals Biopharmaceutical CDMO Introduction
11.15.4 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.15.5 3P Biopharmaceuticals Recent Developments
11.16 Rentschler Biopharma
11.16.1 Rentschler Biopharma Company Details
11.16.2 Rentschler Biopharma Business Overview
11.16.3 Rentschler Biopharma Biopharmaceutical CDMO Introduction
11.16.4 Rentschler Biopharma Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.16.5 Rentschler Biopharma Recent Developments
11.17 Northway Biotech
11.17.1 Northway Biotech Company Details
11.17.2 Northway Biotech Business Overview
11.17.3 Northway Biotech Biopharmaceutical CDMO Introduction
11.17.4 Northway Biotech Revenue in Biopharmaceutical CDMO Business (2018-2023)
11.17.5 Northway Biotech Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Biopharmaceutical CDMO Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Development and Manufacturing CDMOs
Table 3. Key Players of Clinical Trial Material CDMOs
Table 4. Key Players of Fill-Finish CDMOs
Table 5. Key Players of Other
Table 6. Global Biopharmaceutical CDMO Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 7. Global Biopharmaceutical CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Biopharmaceutical CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Biopharmaceutical CDMO Market Share by Region (2018-2023)
Table 10. Global Biopharmaceutical CDMO Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Biopharmaceutical CDMO Market Share by Region (2024-2033)
Table 12. Biopharmaceutical CDMO Market Trends
Table 13. Biopharmaceutical CDMO Market Drivers
Table 14. Biopharmaceutical CDMO Market Challenges
Table 15. Biopharmaceutical CDMO Market Restraints
Table 16. Global Biopharmaceutical CDMO Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Biopharmaceutical CDMO Revenue Share by Players (2018-2023)
Table 18. Global Top Biopharmaceutical CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceutical CDMO as of 2022)
Table 19. Global Biopharmaceutical CDMO Industry Ranking 2021 VS 2022 VS 2023
Table 20. Global 5 Largest Players Market Share by Biopharmaceutical CDMO Revenue (CR5 and HHI) & (2018-2023)
Table 21. Global Key Players of Biopharmaceutical CDMO, Headquarters and Area Served
Table 22. Global Key Players of Biopharmaceutical CDMO, Product and Application
Table 23. Global Key Players of Biopharmaceutical CDMO, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Biopharmaceutical CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Biopharmaceutical CDMO Revenue Market Share by Type (2018-2023)
Table 27. Global Biopharmaceutical CDMO Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Biopharmaceutical CDMO Revenue Market Share by Type (2024-2033)
Table 29. Global Biopharmaceutical CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Biopharmaceutical CDMO Revenue Share by Application (2018-2023)
Table 31. Global Biopharmaceutical CDMO Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Biopharmaceutical CDMO Revenue Share by Application (2024-2033)
Table 33. North America Biopharmaceutical CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 34. North America Biopharmaceutical CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 35. North America Biopharmaceutical CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 36. North America Biopharmaceutical CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 37. North America Biopharmaceutical CDMO Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 38. North America Biopharmaceutical CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 39. North America Biopharmaceutical CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 40. Europe Biopharmaceutical CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 41. Europe Biopharmaceutical CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 42. Europe Biopharmaceutical CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 43. Europe Biopharmaceutical CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 44. Europe Biopharmaceutical CDMO Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 45. Europe Biopharmaceutical CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 46. Europe Biopharmaceutical CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 47. China Biopharmaceutical CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 48. China Biopharmaceutical CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 49. China Biopharmaceutical CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 50. China Biopharmaceutical CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 51. Asia Biopharmaceutical CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 52. Asia Biopharmaceutical CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 53. Asia Biopharmaceutical CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 54. Asia Biopharmaceutical CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 55. Asia Biopharmaceutical CDMO Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 56. Asia Biopharmaceutical CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 57. Asia Biopharmaceutical CDMO Market Size by Region (2024-2033) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Biopharmaceutical CDMO Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 63. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 65. Lonza Company Details
Table 66. Lonza Business Overview
Table 67. Lonza Biopharmaceutical CDMO Product
Table 68. Lonza Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 69. Lonza Recent Developments
Table 70. WuXi AppTec Company Details
Table 71. WuXi AppTec Business Overview
Table 72. WuXi AppTec Biopharmaceutical CDMO Product
Table 73. WuXi AppTec Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 74. WuXi AppTec Recent Developments
Table 75. Catalent Company Details
Table 76. Catalent Business Overview
Table 77. Catalent Biopharmaceutical CDMO Product
Table 78. Catalent Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 79. Catalent Recent Developments
Table 80. Thermo Fisher Company Details
Table 81. Thermo Fisher Business Overview
Table 82. Thermo Fisher Biopharmaceutical CDMO Product
Table 83. Thermo Fisher Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 84. Thermo Fisher Recent Developments
Table 85. Recipharm Company Details
Table 86. Recipharm Business Overview
Table 87. Recipharm Biopharmaceutical CDMO Product
Table 88. Recipharm Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 89. Recipharm Recent Developments
Table 90. Samsung Biologics Company Details
Table 91. Samsung Biologics Business Overview
Table 92. Samsung Biologics Biopharmaceutical CDMO Product
Table 93. Samsung Biologics Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 94. Samsung Biologics Recent Developments
Table 95. Siegfried Company Details
Table 96. Siegfried Business Overview
Table 97. Siegfried Biopharmaceutical CDMO Product
Table 98. Siegfried Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 99. Siegfried Recent Developments
Table 100. Delpharm Company Details
Table 101. Delpharm Business Overview
Table 102. Delpharm Biopharmaceutical CDMO Product
Table 103. Delpharm Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 104. Delpharm Recent Developments
Table 105. Boehringer Ingelheim Company Details
Table 106. Boehringer Ingelheim Business Overview
Table 107. Boehringer Ingelheim Biopharmaceutical CDMO Product
Table 108. Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 109. Boehringer Ingelheim Recent Developments
Table 110. Aenova Group Company Details
Table 111. Aenova Group Business Overview
Table 112. Aenova Group Biopharmaceutical CDMO Product
Table 113. Aenova Group Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 114. Aenova Group Recent Developments
Table 115. AGC Parma Chemicals Company Details
Table 116. AGC Parma Chemicals Business Overview
Table 117. AGC Parma Chemicals Biopharmaceutical CDMO Product
Table 118. AGC Parma Chemicals Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 119. AGC Parma Chemicals Recent Developments
Table 120. GenScript Company Details
Table 121. GenScript Business Overview
Table 122. GenScript Biopharmaceutical CDMO Product
Table 123. GenScript Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 124. GenScript Recent Developments
Table 125. ProBioGen Company Details
Table 126. ProBioGen Business Overview
Table 127. ProBioGen Biopharmaceutical CDMO Product
Table 128. ProBioGen Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 129. ProBioGen Recent Developments
Table 130. KBI Biopharma Company Details
Table 131. KBI Biopharma Business Overview
Table 132. KBI Biopharma Biopharmaceutical CDMO Product
Table 133. KBI Biopharma Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 134. KBI Biopharma Recent Developments
Table 135. 3P Biopharmaceuticals Company Details
Table 136. 3P Biopharmaceuticals Business Overview
Table 137. 3P Biopharmaceuticals Biopharmaceutical CDMO Product
Table 138. 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 139. 3P Biopharmaceuticals Recent Developments
Table 140. Rentschler Biopharma Company Details
Table 141. Rentschler Biopharma Business Overview
Table 142. Rentschler Biopharma Biopharmaceutical CDMO Product
Table 143. Rentschler Biopharma Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 144. Rentschler Biopharma Recent Developments
Table 145. Northway Biotech Company Details
Table 146. Northway Biotech Business Overview
Table 147. Northway Biotech Biopharmaceutical CDMO Product
Table 148. Northway Biotech Revenue in Biopharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 149. Northway Biotech Recent Developments
Table 150. Research Programs/Design for This Report
Table 151. Key Data Information from Secondary Sources
Table 152. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Biopharmaceutical CDMO Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Biopharmaceutical CDMO Market Share by Type: 2022 VS 2033
Figure 3. Development and Manufacturing CDMOs Features
Figure 4. Clinical Trial Material CDMOs Features
Figure 5. Fill-Finish CDMOs Features
Figure 6. Other Features
Figure 7. Global Biopharmaceutical CDMO Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 8. Global Biopharmaceutical CDMO Market Share by Application: 2022 VS 2033
Figure 9. Pharmaceutical Company Case Studies
Figure 10. Biotechnology Company Case Studies
Figure 11. Other Case Studies
Figure 12. Biopharmaceutical CDMO Report Years Considered
Figure 13. Global Biopharmaceutical CDMO Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Biopharmaceutical CDMO Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Biopharmaceutical CDMO Market Share by Region: 2022 VS 2033
Figure 16. Global Biopharmaceutical CDMO Market Share by Players in 2022
Figure 17. Global Top Biopharmaceutical CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceutical CDMO as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Biopharmaceutical CDMO Revenue in 2022
Figure 19. North America Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Biopharmaceutical CDMO Market Share by Type (2018-2033)
Figure 21. North America Biopharmaceutical CDMO Market Share by Application (2018-2033)
Figure 22. North America Biopharmaceutical CDMO Market Share by Country (2018-2033)
Figure 23. United States Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Canada Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe Biopharmaceutical CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 26. Europe Biopharmaceutical CDMO Market Share by Type (2018-2033)
Figure 27. Europe Biopharmaceutical CDMO Market Share by Application (2018-2033)
Figure 28. Europe Biopharmaceutical CDMO Market Share by Country (2018-2033)
Figure 29. Germany Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. France Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. U.K. Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Italy Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Russia Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Nordic Countries Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. China Biopharmaceutical CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 36. China Biopharmaceutical CDMO Market Share by Type (2018-2033)
Figure 37. China Biopharmaceutical CDMO Market Share by Application (2018-2033)
Figure 38. Asia Biopharmaceutical CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 39. Asia Biopharmaceutical CDMO Market Share by Type (2018-2033)
Figure 40. Asia Biopharmaceutical CDMO Market Share by Application (2018-2033)
Figure 41. Asia Biopharmaceutical CDMO Market Share by Region (2018-2033)
Figure 42. Japan Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. South Korea Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. China Taiwan Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Southeast Asia Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. India Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Australia Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Share by Type (2018-2033)
Figure 50. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Share by Application (2018-2033)
Figure 51. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Share by Country (2018-2033)
Figure 52. Brazil Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 53. Mexico Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. Turkey Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. Saudi Arabia Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. Israel Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 57. GCC Countries Biopharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 58. Lonza Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 59. WuXi AppTec Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 60. Catalent Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 61. Thermo Fisher Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 62. Recipharm Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 63. Samsung Biologics Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 64. Siegfried Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 65. Delpharm Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 66. Boehringer Ingelheim Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 67. Aenova Group Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 68. AGC Parma Chemicals Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 69. GenScript Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 70. ProBioGen Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 71. KBI Biopharma Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 72. 3P Biopharmaceuticals Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 73. Rentschler Biopharma Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 74. Northway Biotech Revenue Growth Rate in Biopharmaceutical CDMO Business (2018-2023)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries